Microparticles containing erlotinib-loaded solid lipid nanoparticles for treatment of non-small cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Microparticles containing erlotinib-loaded solid lipid nanoparticles for treatment of non-small cell lung cancer

Published:2017-04-10 Issue:8 Volume:43 Page:1244-1253
ISSN:0363-9045
Container-title:Drug Development and Industrial Pharmacy
language:en
Short-container-title:Drug Development and Industrial Pharmacy

Author:

Bakhtiary Zahra¹,Barar Jaleh²³^ORCID,Aghanejad Ayuob²,Saei Amir Ata⁴,Nemati Elhameh²,Ezzati Nazhad Dolatabadi Jafar²,Omidi Yadollah²³^ORCID

Affiliation:

1. Student Research Committee, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran;

2. Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences, Tabriz, Iran;

3. Department of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran;

4. Division of Physiological Chemistry, Department of Medical Biochemistry and Biophysics, KarolinskaInstitutet, Stockholm, Sweden

Funder

Tabriz University of Medical Sciences

Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences

Publisher

Informa UK Limited

Subject

Organic Chemistry,Drug Discovery,Pharmaceutical Science,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/03639045.2017.1310223

Reference44 articles.

1. Targeted therapy for NSCLC with driver mutations

2. New driver mutations in non-small-cell lung cancer

3. American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy

4. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

5. Solid lipid nanoparticles (SLN) for controlled drug delivery â a review of the state of the art

Cited by 115 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revolutionizing Lung Cancer Treatment: Nanotechnology-Driven Advances in Targeted Drug Delivery and Novel Therapeutic Strategies;Journal of Drug Delivery Science and Technology;2024-09

2. Harnessing nanotechnology for enhanced delivery of erlotinib: a dynamic duo in cancer treatment;Beni-Suef University Journal of Basic and Applied Sciences;2024-07-26

3. Molecular Mechanism of Novel PAMAM Dendrimer Decorated Tectona grandis and Lactobacillus plantarum Nanoparticles on Autophagy-Induced Apoptosis in TNBC Cells;BioNanoScience;2024-07-17

4. Nanoparticle-based targeted therapy through EGFR tyrosine kinase inhibitors and their recent advances in lung cancer therapy;Exploration of Medicine;2024-07-14

5. Multifaceted role of erlotinib in various cancer: nanotechnology intervention, patent landscape, and advancements in clinical trials;Medical Oncology;2024-06-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3